首页> Multiple sclerosis (Houndmills, Basingstoke, England)> Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS.

导出 OA

翻译打印收藏纠错

第一作者： Marcus W,Koch

第一单位： Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

作者： Marcus W,Koch ^[1] ; Carlos,Camara-Lemarroy ^[1] ; Eva,Strijbis ^[2] ; Jop,Mostert ^[3] ; Victoria M,Leavitt ^[4] ; Pavle,Repovic ^[5] ; James D,Bowen ^[5] ; Jacynthe,Comtois ^[6] ; Bernard,Uitdehaag ^[2] ; Gary,Cutter ^[7]

作者单位： Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. ^[1] Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands. ^[2] Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands. ^[3] Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA. ^[4] Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA. ^[5] Department of Medicine, Neurology Service, Hôpital de la Cité-de-la-Santé, Laval, QC, Canada. ^[6] Department of Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, USA. ^[7]

关键词 Clinical trial atrophy disease modifying therapies outcome measurement progressive

医学主题词人类(Humans);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);多发性硬化, 慢性进行性(Multiple Sclerosis, Chronic Progressive);病人遴选(Patient Selection);研究设计(Research Design)

DOI 10.1177/13524585241274620

PMID 39245930

发布时间 2024-12-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交